Subscribe
emiliaungur-shutterstock-com
EmiliaUngur / Shutterstock.com
17 August 2015Americas

FFC claims Allergan’s complaint violates anti-SLAPP laws

US hedge fund Ferrum Ferro Capital (FFC) has asked a California court to reject Allergan’s complaint about malicious prosecution because it allegedly violates a state law designed to stop parties from intentionally burdening another party with a legal complaint.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Allergan survives Combigan patent challenge
29 September 2015   Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital to invalidate a patent covering its Combigan drug after the Patent Trial and Appeal Board opted not to institute an inter partes review.


Editor's picks

Bankruptcy judge approves $305m sale of genetics testing company
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025

Editor's picks

Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025

More on this story

Americas
Allergan survives Combigan patent challenge
29 September 2015   Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital to invalidate a patent covering its Combigan drug after the Patent Trial and Appeal Board opted not to institute an inter partes review.

More on this story

Americas
Allergan survives Combigan patent challenge
29 September 2015   Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital to invalidate a patent covering its Combigan drug after the Patent Trial and Appeal Board opted not to institute an inter partes review.

More features

Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations